Roche's Evrysdi wins EU approval for spinal muscular atrophy

Health News
FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen, in Burgess Hill, Britain, October 7, 2020. REUTERS/Peter Nicholls

ZURICH (Reuters) – Roche’s Evrysdi has won approval from the European Commission as the first and only at-home treatment for spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday.

It has been approved for treating 5q SMA in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies, it said.

The drugmaker said it was working with reimbursement and assessment bodies in European countries to enable broad and rapid access. Rival treatments include Zolgensma from Novartis and Biogen’s Spinraza.

Source: Read Full Article

Related posts:
  1. UK startup develops gyroscope glove to ease tremors for those with Parkinson's
  2. U.S. health body questions AstraZeneca's COVID-19 vaccine trial data
  3. Canada pauses AstraZeneca COVID-19 vaccine use for those under 55, wants new risk analysis
  4. Novartis says Kesimpta gets EU approval in multiple sclerosis
  5. Spain widens use of AstraZeneca vaccine as cases rise again